PURPOSE OF REVIEW: The transplant community has seen the gradual acceptance of liver and kidney transplantation in carefully selected HIV-positive patients. The addition of transplant immunosuppressants to an already immunocompromised state, however, may increase the risk of malignancy. RECENT FINDINGS: Kidney transplantation and liver transplantation have been successful in large series of carefully selected HIV-infected patients, with graft and patient survival approaching those of non-HIV-infected patients. The incidence of acute cellular rejection (kidney transplantation) and of recurrent hepatitis C (liver transplantation) remains challenging. Hepatocellular carcinoma (HCC), which is a common indication for liver transplantation, seems to occur at a younger age and to have a generally worse outcome in the HIV-positive patients. Liver transplantation outcomes for HCC in these patients, however, do not seem to be compromised. Rates of Kaposi's sarcoma and other de-novo malignancies such as skin cancer are relatively low after transplant. Kaposi's sarcoma may regress with the use of the mammalian target of rapamycin inhibitor sirolimus. In HIV-positive patients followed closely for human papilloma virus (HPV)-related anal neoplasia after transplantation, there may be an increased risk of progression to high-grade squamous intraepithelial lesions. SUMMARY: The risk of recurrent or de-novo malignancy after solid-organ transplantation in HIV patients is low. HPV-related neoplasia, however, requires further study.
PURPOSE OF REVIEW: The transplant community has seen the gradual acceptance of liver and kidney transplantation in carefully selected HIV-positivepatients. The addition of transplant immunosuppressants to an already immunocompromised state, however, may increase the risk of malignancy. RECENT FINDINGS: Kidney transplantation and liver transplantation have been successful in large series of carefully selected HIV-infectedpatients, with graft and patient survival approaching those of non-HIV-infectedpatients. The incidence of acute cellular rejection (kidney transplantation) and of recurrent hepatitis C (liver transplantation) remains challenging. Hepatocellular carcinoma (HCC), which is a common indication for liver transplantation, seems to occur at a younger age and to have a generally worse outcome in the HIV-positivepatients. Liver transplantation outcomes for HCC in these patients, however, do not seem to be compromised. Rates of Kaposi's sarcoma and other de-novo malignancies such as skin cancer are relatively low after transplant. Kaposi's sarcoma may regress with the use of the mammalian target of rapamycin inhibitor sirolimus. In HIV-positivepatients followed closely for human papilloma virus (HPV)-related anal neoplasia after transplantation, there may be an increased risk of progression to high-grade squamous intraepithelial lesions. SUMMARY: The risk of recurrent or de-novo malignancy after solid-organ transplantation in HIV patients is low. HPV-related neoplasia, however, requires further study.
Authors: C S Coffin; P G Stock; L M Dove; C L Berg; N N Nissen; M P Curry; M Ragni; F G Regenstein; K E Sherman; M E Roland; N A Terrault Journal: Am J Transplant Date: 2010-03-19 Impact factor: 8.086
Authors: Giovanni Stallone; Antonio Schena; Barbara Infante; Salvatore Di Paolo; Antonella Loverre; Giulio Maggio; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: Curtis Cooper; Steve Kanters; Marina Klein; Prosanto Chaudhury; Paul Marotta; Phil Wong; Norman Kneteman; Edward J Mills Journal: AIDS Date: 2011-03-27 Impact factor: 4.177
Authors: F Di Benedetto; G Tarantino; N De Ruvo; N Cautero; R Montalti; G P Guerrini; R Ballarin; M Spaggiari; N Smerieri; V Serra; G Rompianesi; G D'Amico; A Mimmo; R M Iemmolo; M Codeluppi; S Cocchi; G Guaraldi; G E Gerunda Journal: Transplant Proc Date: 2011-05 Impact factor: 1.066
Authors: Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland Journal: N Engl J Med Date: 2010-11-18 Impact factor: 91.245
Authors: Fabrizio Di Benedetto; Stefano Di Sandro; Nicola De Ruvo; Massimiliano Berretta; Michele Masetti; Roberto Montalti; Roberto Ballarin; Stefania Cocchi; Leonardo Potenza; Mario Luppi; Giorgio E Gerunda Journal: J Cancer Res Clin Oncol Date: 2007-10-09 Impact factor: 4.553
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: Umberto Baccarani; Elda Righi; Gian Luigi Adani; Dario Lorenzin; Alberto Pasqualucci; Matteo Bassetti; Andrea Risaliti Journal: World J Gastroenterol Date: 2014-05-14 Impact factor: 5.742
Authors: Elmi Muller; Francois C J Botha; Zunaid A Barday; Kathryn Manning; Peter Chin-Hong; Peter Stock Journal: Transplantation Date: 2021-07-01 Impact factor: 5.385